Bicara Therapeutics’ (BCAX) Market Outperform Rating Reiterated at Citizens Jmp

Bicara Therapeutics (NASDAQ:BCAX)‘s stock had its “market outperform” rating reiterated by Citizens Jmp in a research report issued on Tuesday,Benzinga reports. They currently have a $31.00 target price on the stock. Citizens Jmp’s price objective would suggest a potential upside of 60.08% from the company’s current price.

BCAX has been the topic of a number of other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Friday, January 9th. Bank of America began coverage on shares of Bicara Therapeutics in a research note on Wednesday, March 25th. They issued a “buy” rating and a $35.00 target price on the stock. BTIG Research reissued a “buy” rating on shares of Bicara Therapeutics in a report on Thursday, January 15th. UBS Group reaffirmed a “buy” rating on shares of Bicara Therapeutics in a report on Wednesday, January 14th. Finally, Mizuho upgraded Bicara Therapeutics to a “hold” rating in a research report on Thursday, December 18th. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $28.88.

Bicara Therapeutics Price Performance

Shares of Bicara Therapeutics stock opened at $19.37 on Tuesday. Bicara Therapeutics has a 1-year low of $7.80 and a 1-year high of $20.25. The business has a 50-day moving average of $17.15 and a 200-day moving average of $16.61. The company has a market capitalization of $1.06 billion, a PE ratio of -8.65 and a beta of -0.78.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Monday, March 30th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.04. On average, equities analysts expect that Bicara Therapeutics will post -2.59 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Bicara Therapeutics news, COO Ryan Cohlhepp sold 17,392 shares of the stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $18.16, for a total value of $315,838.72. Following the transaction, the chief operating officer owned 205,141 shares of the company’s stock, valued at approximately $3,725,360.56. This represents a 7.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Claire Mazumdar sold 36,766 shares of the firm’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $19.17, for a total value of $704,804.22. Following the transaction, the chief executive officer owned 339,392 shares in the company, valued at approximately $6,506,144.64. This trade represents a 9.77% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 137,969 shares of company stock valued at $2,586,198 over the last 90 days.

Institutional Trading of Bicara Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of BCAX. Legal & General Group Plc raised its position in shares of Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after acquiring an additional 1,233 shares during the period. Ameritas Investment Partners Inc. grew its holdings in Bicara Therapeutics by 73.0% during the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock valued at $32,000 after purchasing an additional 1,474 shares during the period. Tower Research Capital LLC TRC increased its stake in Bicara Therapeutics by 419.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after purchasing an additional 3,866 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Bicara Therapeutics in the fourth quarter worth $45,000. Finally, Larson Financial Group LLC raised its holdings in Bicara Therapeutics by 1,015.5% in the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after purchasing an additional 3,595 shares during the period.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.